Departments of Pharmacology and Toxicology, Michigan State University, East Lansing, Michigan 48824-1224, USA.
J Toxicol Environ Health A. 2010;73(1):58-73. doi: 10.1080/15287390903249057.
Acetaminophen (APAP)-induced hepatotoxicity accounts for nearly half of acute liver failure cases in the United States. The doses that produce hepatotoxicity vary considerably and many risk factors have been proposed, including liver inflammation from viral hepatitis. Interestingly, inflammatory stress from another stimulus, bacterial endotoxin (lipopolysaccharide, LPS), renders the liver more sensitive to hepatotoxicity from numerous xenobiotic agents. The purpose of these studies was to test the hypothesis that inflammation induced by LPS or infection with reovirus increases sensitivity to APAP-induced liver injury. For LPS-induced inflammation, C57BL/6J mice were treated with either saline or LPS (44 x 10(6) EU/kg, ip) 2 h before treatment with APAP (100-400 mg/kg, ip) or saline. No elevation in serum alanine aminotransferase (ALT) activity was observed in mice that received vehicle or LPS alone. LPS co-treatment produced a leftward shift of the dose-response curve for APAP-induced hepatotoxicity and led to significantly greater tumor necrosis factor-alpha (TNF) production than APAP alone. Reovirus serotype 1 (10(8) PFU, iv) induced inflammation in Balb/c mice as evidenced by increases in hepatic mRNAs for macrophage inhibitory protein-2, interleukin-6, and TNF. Co-administration of reovirus and APAP at doses of 450 and 700 mg/kg (2 h after reovirus) led to increases in serum ALT activity, whereas neither reovirus nor APAP alone produced liver injury. Consistent with the increases in serum ALT activity, histopathologic examination revealed centrilobular necrosis with marked neutrophilic accumulation only in livers of mice treated with LPS/APAP or with reovirus/APAP. The results suggest that normally noninjurious doses of APAP are rendered hepatotoxic by modest inflammation, whether bacterial or viral in origin.
对乙酰氨基酚(APAP)诱导的肝毒性占美国急性肝衰竭病例的近一半。产生肝毒性的剂量差异很大,提出了许多危险因素,包括来自病毒性肝炎的肝炎症。有趣的是,来自另一种刺激物,细菌内毒素(脂多糖,LPS)的炎症应激使肝脏对来自许多外源生物试剂的肝毒性更加敏感。这些研究的目的是检验以下假说:LPS 诱导的炎症或呼肠孤病毒感染会增加对 APAP 诱导的肝损伤的敏感性。对于 LPS 诱导的炎症,C57BL/6J 小鼠在用 LPS(44 x 10(6) EU/kg,ip)处理 2 小时后用 APAP(100-400 mg/kg,ip)或盐水处理。单独给予载体或 LPS 的小鼠中未观察到血清丙氨酸氨基转移酶(ALT)活性升高。LPS 共同处理导致 APAP 诱导的肝毒性的剂量反应曲线向左移位,并导致 TNF 产生量明显高于 APAP 单独处理。肠道病毒 1 型(10(8)PFU,iv)诱导 Balb/c 小鼠炎症,表现为肝脏巨噬细胞抑制蛋白-2、白细胞介素-6 和 TNF 的 mRNA 增加。APAP 在 450 和 700 mg/kg(病毒后 2 小时)与 LPS 共同给药导致血清 ALT 活性增加,而单独使用 LPS 或 APAP 均未导致肝损伤。与血清 ALT 活性增加一致,组织病理学检查显示仅在 LPS/APAP 或呼肠孤病毒/APAP 处理的小鼠肝脏中观察到中央小叶坏死,伴有明显的中性粒细胞聚集。结果表明,通常非损伤性剂量的 APAP 被适度炎症(无论是细菌还是病毒来源)转化为肝毒性。